{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:47:43Z","timestamp":1782931663496,"version":"3.54.5"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Quality and Outcomes"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>A worldwide voluntary recall of valsartan in July 2018 due to the potential carcinogen N-nitrosodimethylamine received extensive media and public attention. This was followed by more Food and Drug Administration (FDA) recalls regarding other contaminated ARB (angiotensin receptor blocker) products. Our study investigated the association between the FDA recalls and ARB neoplasm adverse events (AEs) reported to the FDA adverse event reporting system.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>\n              In this cross-sectional study, data were retrospectively collected from the FDA adverse event reporting system database from January 2015 to December 2019. Reporting odds ratios (RORs) were estimated to detect signals of association between ARBs (valsartan, irbesartan, and losartan) and reported neoplasm AEs using negative (amoxicillin and sertraline) and positive (omeprazole and ranitidine) control exposures. The \u03c7\n              <jats:sup>2<\/jats:sup>\n              was used to compare categorical variables.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>\n              A total of 2\u2009181\u2009524 AEs, including 10\u2009461 nonmetastatic neoplasm AEs were analyzed. Monthly RORs (95% CI) of valsartan-associated neoplasms versus controls (ROR*: valsartan\/negative exposures; ROR\u2020: valsartan\/omeprazole; and ROR\u2021: valsartan\/ranitidine) showed the highest signals after the recall date in July 2018 (7.64 [4.78\u201312.19]*; 4.77 [3.36\u20136.79]\u2020; 4.13 [2.50\u20136.84]\u2021) and August 2018 (7.87 [5.19\u201311.94]*; 5.65 [4.12\u20137.75]\u2020; and 7.20 [4.46\u201311.63]\u2021). In contrast, the highest cancer signals for the irbesartan and losartan recalls detected in March 2019 (4.80*; 4.06\u2020; and 3.38\u2021) and April 2019 (3.63*; 3.69\u2020; and 2.52\u2021) respectively, were lower. One-year postrecall reported neoplasm AEs were \u22482-fold higher for valsartan than irbesartan (OR, 1.77 [95% CI, 1.47\u20132.13],\n              <jats:italic>P<\/jats:italic>\n              &lt;0.0001) and losartan (OR, 2.07 [95% CI, 1.85\u20132.32],\n              <jats:italic>P<\/jats:italic>\n              &lt;0.0001). Although all ARBs had the same nitrosamine contamination, we found 1-year postrecall versus prerecall cancer signals for valsartan were 3-fold higher versus control exposures, while the changes in RORs for irbesartan and losartan were only 20-30% higher.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Significantly more postrecall neoplasms were reported for valsartan, with higher valsartan-associated cancer signals compared with irbesartan and losartan, although they all contained the same carcinogenic contaminant. Extensive media coverage of the FDA valsartan recall may have alarmed patients and generated these abrupt, biologically infeasible cancer signals.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circoutcomes.120.007476","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T09:00:29Z","timestamp":1628758829000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls"],"prefix":"10.1161","volume":"14","author":[{"given":"Robert","family":"Cohen Sedgh","sequence":"first","affiliation":[{"name":"Western University of Health Sciences, Pomona, CA (R.C.S., J.M., C.A.J.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-6953","authenticated-orcid":true,"given":"Jungyeon","family":"Moon","sequence":"additional","affiliation":[{"name":"Western University of Health Sciences, Pomona, CA (R.C.S., J.M., C.A.J.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5274-7251","authenticated-orcid":true,"given":"Cynthia A.","family":"Jackevicius","sequence":"additional","affiliation":[{"name":"Western University of Health Sciences, Pomona, CA (R.C.S., J.M., C.A.J.)."},{"name":"VA Greater Los Angeles Healthcare System, CA (C.A.J.)."},{"name":"Institute for Clinical Evaluative Sciences, Toronto, Canada (C.A.J.)."},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Canada (C.A.J.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.04.025"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.10.824"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06214-1"},{"key":"e_1_3_6_6_2","unstructured":"Food and Drug Administration. FDA updates and press announcements on angiotensin II receptor blocker (ARB) recalls (valsartan losartan and irbesartan). Accessed April 16 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.5487\/TR.2015.31.3.279"},{"key":"e_1_3_6_8_2","unstructured":"United States Environmental Protection Agency. Technical fact sheet \u2013 N-nitroso-dimethylamine (NDMA) November 2017. Accessed April 20 2020. https:\/\/www.epa.gov\/sites\/production\/files\/2017-10\/documents\/ndma_fact_sheet_update_9-15-17_508.pdf"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3851"},{"key":"e_1_3_6_10_2","unstructured":"European Medicines Agency. Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group. Accessed April 16 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019897388"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044494"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005536"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048"},{"key":"e_1_3_6_15_2","first-page":"405","article-title":"Safety signal detection for platinum compounds in Canadian Spontaneous Adverse Event Reports.","volume":"7","author":"Singhal S","year":"2015","unstructured":"Singhal, S, Bhaswat, C. Safety signal detection for platinum compounds in Canadian Spontaneous Adverse Event Reports. Int J Pharm Sci. 2015;7:405\u2013411.","journal-title":"Int J Pharm Sci"},{"key":"e_1_3_6_16_2","unstructured":"Food and Drug Administration. Search list of recalled angiotensin II receptor blockers (ARBs) including valsartan losartan and irbesartan. Accessed April 16 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/search-list-recalled-angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx213"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181d61eeb"},{"key":"e_1_3_6_19_2","unstructured":"IQVIA. Medicine use and spending in the US - a review of 2018 outlook to 2023. Accessed March 25 2020. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/medicine-use-and-spending-in-the-us---a-review-of-2018-outlook-to-2023.pdf?_=1589578554435"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2307-y"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13498"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e328355e289"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0401"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320826"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i16.2560"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14796"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017739"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1557(200003\/04)9:2<149::AID-PDS481>3.0.CO;2-1"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcz234"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.086579"},{"key":"e_1_3_6_31_2","unstructured":"Food and Drug Administration. FDA Updates and press announcements on NDMA in Zantac (ranitidine). Accessed April 16 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-ndma-zantac-ranitidine"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0962280211403602"},{"key":"e_1_3_6_33_2","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1-42. Lyon (FR): International Agency for Research on Cancer; 1987. (IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS No. Supplement 7.) www.ncbi.nlm.nih.gov\/books\/NBK533509\/"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1218(91)90123-4"},{"key":"e_1_3_6_36_2","first-page":"627","article-title":"Nitrosamine carcinogenesis in 5120 rodents: chronic administration of sixteen different concentrations of NDEA, NDMA, NPYR and NPIP in the water of 4440 inbred rats, with parallel studies on NDEA alone of the effect of age of starting (3, 6 or 20 weeks) and of species (rats, mice or hamsters).","author":"Peto R","year":"1984","unstructured":"Peto, R, Gray, R, Brantom, P, Grasso, P. Nitrosamine carcinogenesis in 5120 rodents: chronic administration of sixteen different concentrations of NDEA, NDMA, NPYR and NPIP in the water of 4440 inbred rats, with parallel studies on NDEA alone of the effect of age of starting (3, 6 or 20 weeks) and of species (rats, mice or hamsters). IARC Sci Publ. 1984;627\u2013665.","journal-title":"IARC Sci Publ"},{"key":"e_1_3_6_37_2","unstructured":"Agency for Toxic Substances and Disease Registry U.S. Public Health Service. Toxicological profile for N-nitrosodimethylamine. 1989. Accessed April 20 2020. https:\/\/www.atsdr.cdc.gov\/toxprofiles\/tp141.pdf"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(84)90047-8"},{"key":"e_1_3_6_39_2","unstructured":"Food and Drug Administration. FDA statement on FDA\u2019s ongoing investigation into valsartan impurities and recalls and an update on FDA\u2019s current findings. Accessed April 16 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-statement-fdas-ongoing-investigation-valsartan-impurities-and-recalls-and-update-fdas-current"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.17521"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.2940070410"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.012377"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114513003462"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0215(19990315)80:6<852::aid-ijc9>3.0.co;2-s"},{"key":"e_1_3_6_45_2","unstructured":"Google Trends for valsartan\/irbesartan\/losartan-recall. Accessed April 16 2020. https:\/\/trends.google.com\/trends\/explore?date=2015-01-01%202019-12-31&q=valsartan%20recall losartan%20recall irbesartan%20recall"}],"container-title":["Circulation: Cardiovascular Quality and Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCOUTCOMES.120.007476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T03:37:49Z","timestamp":1715571469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCOUTCOMES.120.007476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1161\/CIRCOUTCOMES.120.007476"],"URL":"https:\/\/doi.org\/10.1161\/circoutcomes.120.007476","relation":{},"ISSN":["1941-7713","1941-7705"],"issn-type":[{"value":"1941-7713","type":"print"},{"value":"1941-7705","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"2020-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e007476"}}